Asset Details
Do you wish to reserve the book?
A multiplex implantable microdevice assay identifies synergistic combinations of cancer immunotherapies and conventional drugs
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
A multiplex implantable microdevice assay identifies synergistic combinations of cancer immunotherapies and conventional drugs
Do you wish to request the book?
A multiplex implantable microdevice assay identifies synergistic combinations of cancer immunotherapies and conventional drugs
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
A multiplex implantable microdevice assay identifies synergistic combinations of cancer immunotherapies and conventional drugs
2022
Overview
Systematically identifying synergistic combinations of targeted agents and immunotherapies for cancer treatments remains difficult. In this study, we integrated high-throughput and high-content techniques—an implantable microdevice to administer multiple drugs into different sites in tumors at nanodoses and multiplexed imaging of tumor microenvironmental states—to investigate the tumor cell and immunological response signatures to different treatment regimens. Using a mouse model of breast cancer, we identified effective combinations from among numerous agents within days. In vivo studies in three immunocompetent mammary carcinoma models demonstrated that the predicted combinations synergistically increased therapeutic efficacy. We identified at least five promising treatment strategies, of which the panobinostat, venetoclax and anti-CD40 triple therapy was the most effective in inducing complete tumor remission across models. Successful drug combinations increased spatial association of cancer stem cells with dendritic cells during immunogenic cell death, suggesting this as an important mechanism of action in long-term breast cancer control.
Testing of combinations of cancer immunotherapies and conventional drugs yields promising leads.
Publisher
Nature Publishing Group US,Nature Publishing Group
Subject
